Every intervention Outliyr has scored for kidney health, ranked by its BioHarmony score for this use case rather than its overall rating. The number beside each name is how well that one thing works for kidney health; the tier beside it is what it is worth once safety, cost and effort are counted across everything else.
24 of 94 evaluated interventions score 3.0+ out of 10 for kidney health · 4 comparisons
Perkovic 2024 found 24% lower major kidney disease or death composite risk in type 2 diabetes with CKD. That is a meaningful clinical endpoint, not a wellness proxy. Semaglutide looks most useful…
Justice et al. 2019 gives the strongest anchor. Hickson 2019 reported D+Q senescence-marker reductions in diabetic kidney disease, but it was small, preliminary, and later corrected. The score stays bounded because Senolytics…
Kidney protection is now a proven, indication-level benefit rather than an inference. In the FLOW trial, semaglutide cut the risk of major kidney disease events and death 24% in people with type…
Kidney relevance is most credible in type 2 diabetes and cardiometabolic risk. Weight, glucose, blood pressure, and albuminuria risk factors all improve. SURPASS CVOT improved some kidney metrics versus dulaglutide. The primary…
Soh 2024 anchors the most relevant signal. Glycine fits kidney function because glycine participates in sleep signaling, glutathione, collagen, methylation, and nervous-system balance, depending on the endpoint. The score stays bounded because…
Filip 2007 gives the most relevant evidence anchor. The existing rationale points to this narrower claim: the cited study hemodialysis literature supports biochemical context in dialysis patients, but the prior supplied PMID…
Wang et al. 2023 reported that ERR agonism reversed mitochondrial dysfunction and reduced inflammatory markers in aged mouse kidneys, showing a clear mechanistic link to renal health. However, the findings remain limited…
Higher fitness and better blood pressure control are relevant to kidney-risk reduction, but Zone 2 is not a kidney-specific therapy. CKD patients should individualize intensity, hydration, blood pressure monitoring, and medication timing…
Healthy kidneys handle typical EAA doses, but CKD stage 4-5 requires clinician supervision because nitrogen handling matters. This use case is a caution area, not a benefit claim.
No direct kidney-function evidence. Avoid extrapolating circulation claims into renal benefit claims.
Birk 2013 showed renal ischemia protection and ATP recovery in preclinical models; no positive human renal endpoint trial was verified.
The best-replicated non-metabolic signal. BAM15 dose-dependently protected mice from acute renal ischemia-reperfusion injury in its founding paper (Kenwood et al. 2014) and treated sepsis-associated kidney injury in a high-impact follow-up (Tsuji et…
INSUFFICIENT_EVIDENCE for healthy kidney optimization; transplant history proves use in renal medicine but not kidney-function enhancement in healthy users.
Standardized-extract trials such as Chen 2014 did not show clinically meaningful kidney-marker changes over short windows. No kidney-benefit evidence supports a higher score.
Hickson 2019 used D plus Q in 9 diabetic kidney disease patients and reduced adipose and skin senescence markers within 11 days; clinical renal endpoints were not powered. Ferry 1996 phase 1…
No clear positive or negative kidney-function signal in verified human outcome data.
Late-life dosing prevented an age-related plasma creatinine rise and restored kidney markers in aged mice (Kepchia et al. 2021). Preclinical, and a secondary finding.
Adequate hydration supports renal function, but potassium-heavy supplementation is contraindication-sensitive in chronic kidney disease and interacting medications.
Contrast-induced nephropathy prevention is the headline kidney claim, and it is settled negative: the large ACT (2011) and PRESERVE (2018) trials found NAC no better than placebo. Early small-trial enthusiasm did not…
Some animal nephroprotection data exists, but direct human renal-outcome evidence is lacking.
Some small signals in CoQ10-deficiency-related nephropathy and dialysis populations, but no broad renal-outcome evidence for general use.
Kidney support is mechanistic only, with antioxidant protection of renal tissue but no GlyNAC-specific human outcome trial.
TRT is not kidney-protective. TRAVERSE raised enough kidney-safety concern to keep chronic kidney disease users in a cautious monitoring lane, especially when blood pressure, hematocrit, and edema are unstable.
O. sinensis preparations improved markers in dialysis patients (Liu 2024 meta-analysis, low certainty), but chaga is a documented cause of oxalate kidney injury, so the net class picture is mixed and dose-dependent.
Nothing matches those filters.
Monthly out-of-pocket cost at the most accessible legitimate channel, at the dose the score was given for. 7 of 24 are not priced yet; those cells are left blank rather than guessed.
| Intervention | Monthly cost | At dose | How you get it |
|---|---|---|---|
| Semaglutide | $199–$349 | 0.25 mg weeks 1 to 4, 0.5 mg weeks 5 to 8, 1.0 mg weeks 9 to 12, 1.7 mg weeks 13 to 16, 2.4 mg week 17 onward | Prescription |
| Senolytics | Not priced yet | ||
| GLP-1 Receptor Agonists | Not priced yet | ||
| Tirzepatide | $299–$449 | 2.5 to 5 to 7.5 to 10 to 12.5 to 15 mg | Prescription |
| Glycine | $2–$3 | 3 g oral glycine | Over the counter |
| Ca-AKG (Calcium Alpha-Ketoglutarate) | $15–$30 | 1 g/day generic Ca-AKG oral | Over the counter |
| SLU-PP-332 | $30–$80 | 3-5 mg/day oral | Research use only |
| Zone 2 Cardio | Not priced yet | Over the counter | |
| Essential Amino Acids | Not priced yet | ||
| Whole-Body Vibration | $50–$100 | 30 Hz, roughly 0.3g, 10-20 min standing | Over the counter |
| SS-31 (Elamipretide) | $200–$500 | 5-10 mg/day subcutaneous | Grey market |
| BAM15 | Not priced yet | ||
| Rapamycin | $15–$50 | 3 mg | Prescription |
| Tongkat Ali | $20–$40 | 200 mg/day Physta standardized extract | Over the counter |
| Quercetin | $20–$50 | 200 mg/day | Over the counter |
| Spermidine | $40–$90 | 1-3 mg/day oral WGE | Over the counter |
| J-147 | Not priced yet | ||
| Electrolytes | Not priced yet | ||
| NAC (N-Acetylcysteine) | $5–$15 | 600 to 1,200 mg/day | Over the counter |
| Spirulina | $10–$25 | 1 to 4.5 g/day | Over the counter |
| Coenzyme Q10 (CoQ10 / Ubiquinol) | $15–$40 | 100-200 mg/day | Over the counter |
| GlyNAC (Glycine + N-Acetylcysteine) | $10–$30 | Glycine and NAC at ~100 mg/kg/day each | Over the counter |
| TRT (Testosterone Replacement Therapy) | $50–$300 | Clinician-selected formulation at the lowest dose likely to restore physiologic testosterone | Prescription |
| Adaptogenic Mushrooms (Reishi, Cordyceps, Chaga) | $15–$40 | 1.5 to 1.8 g/day standardized extract | Over the counter |
Head-to-head reports and category rankings that name a winner on this use case.
No. Berberine scores 6.5–7.0/10 and semaglutide 6.0–6.5/10, and that gap misleads almost everyone who reads it. Berberine scores higher because it is cheap, oral and easy to stop,…
Melanotan I is the safer tanning peptide and it scores higher, 6.0–6.5/10 against 4.5–5.0/10. Both darken skin through the same receptor. Melanotan II hits three more receptors, which…
NAC scores 8.0–8.5/10 and glutathione 6.0–6.5/10, and that gap is real. NAC is the cheaper upstream precursor with a six-decade clinical record, so start there. Glutathione earns its…
Tirzepatide scores 6.0–6.5/10 and semaglutide 6.0–6.5/10, so the overall scores don't pick a winner. Your reason for taking one does. Tirzepatide wins on weight and body composition. Semaglutide…
Semaglutide, at 7.0–7.5 out of 10 for kidney health. Perkovic 2024 found 24% lower major kidney disease or death composite risk in type 2 diabetes with CKD.
Of the top-scoring options, Glycine is the least expensive at about $2 a month, scoring 5.5–6.0 out of 10 for kidney health.
24 of the 94 interventions evaluated for kidney health score 3.0 out of 10 or better, which is the cut-off for appearing on this page.
